NEW YORK (GenomeWeb News) — BG Medicine said yesterday that it has withdrawn its registration statement with the US Securities and Exchange Commission for an initial public offering.
 
The Waltham, Mass.-based biomarker and molecular diagnostics maker cited “current market conditions” for its decision not to proceed with the IPO. It did not elaborate on those conditions.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.